Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly stock could soar 140% by 2028 as millions of Americans begin to take their GLP-1 weight loss drugs, according to Goldman Sachs. The firm estimated that if all GLP-1 trials succeed, 68 ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly LLY-2.20 % decrease; red down pointing triangle cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company ...

We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Eli Lilly stock (NYSE: ... The overall growth was driven by Mounjaro’s launch outside of the U.S. and ... Eli Lilly raised its full-year outlook and now expects its sales to be between $45.4 ...

Eli Lilly's strong growth prospects make it a top investment. That's why, while the stock may appear expensive today, it can still be a great buy in the long run as Eli Lilly's business is poised ...

Eli Lilly (LLY 2.29%) has been on an epic run of late. Thanks to the excitement over its Alzheimer's disease and weight-loss assets, Lilly's shares have clobbered the broader markets over the past ...

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Eli Lilly & Co (LLY – Research Report). The associated price target is $650.00. Geoff Meacham has given his Hold ...

By Owen Tucker-Smith . Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in ...